
Conference Coverage
Latest Content

CMS Unveils Initiative to Cut Medicaid Drug Costs and Expand Access to Affordable Medications

Pharma Pulse: FDA Expands Priority Voucher Program, as Oral Semaglutide Shows New Benefits and Cost Plus Drugs Adds Starjemza

Lilly Agreement With Trump Administration Reshapes Patient Access to GLP-1 Obesity Medicines

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

Mark Cuban Cost Plus Drug Company Adds Starjemza to Prescription Drug Portfolio

Shorts










Podcasts
All News

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

Cencora's investment includes new automated centers in Ohio and California and a major cold chain expansion in Alabama to enhance capacity, efficiency, and supply chain resilience.

How next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, faster issue resolution, and greater operational efficiency across the global drug distribution network.

In second part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, urges organizations to move beyond one-time vetting toward continuous monitoring, contractual accountability, and shared responsibility for HIPAA compliance.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

In first part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, explains how excessive data access and poor visibility into data flows remain leading causes of HIPAA-related incidents.

Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.

Lance Hill, CEO of Within3, discusses how AI-driven decision support tools are helping pharmaceutical companies achieve launch excellence while maintaining regulatory compliance and data integrity.

The investment is aimed at boosting oral medicine manufacturing capacity.

In the final part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, emphasizes that as digital tools become central to patient support, there is value to balancing technology with empathy.

The partnership will provide DTC options at locations nationwide.

In the third part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, argues that addressing patients’ emotional barriers is essential to maximizing ROI, improving adherence, and ensuring that existing support programs truly reach those who need them.

In the second part of her Pharma Commerce video interview, Jen Butler, CCO of Pleio, warns that without stronger education, communication, and pharmacist involvement, digital engagement risks becoming purely transactional.

This episode of Pharma Pulse discusses Novartis’ $12 billion acquisition of Avidity Biosciences to expand its RNA therapeutics portfolio, and President Trump’s proposed 10% tariff increase on Canadian imports that could disrupt pharma supply chains.













